*BREAKING: Red flags in new self-amplifying RNA technology*
FLCCC Senior Fellow Dr. Jessica Rose (@JesslovesMJK) discusses concerning updates regarding new self-amplifying RNA products being trialed for #H1N1 in humans.
Read Dr. Rose’s recent articles on this topic on… pic.twitter.com/N486bFg0kL
— FLCCC Alliance (@Honest_Medicine) November 16, 2024
Dr. Jessica Rose takes a hard look at the clinical trial for Arcturus Therapeutics’ self-amplifying RNA vaccine (ARCT-2304) targeting pandemic H5N1 flu. Funded by BARDA, this trial is testing a gene-therapy-based approach using a modified Alphavirus genome, which makes it a GMO.
Dr. Rose has a couple of honest questions:
- Why call this a “pandemic” vaccine already?
- Why push forward a new product with unresolved safety issues from previous mRNA tech?
The important thing to highlight is that this new tech isn’t the same as the COVID mRNA vaccines—not that we don’t have questions about the previous mRNA tech, but this is a different thing entirely. It’s a self-replicating genetic product wrapped in lipid nanoparticles (LNPs). Rose highlights the potential for “forever-copying” genetic material, risks of recombination, and LNP toxicity. She questions whether proper regulatory steps are being followed and whether the public is being primed for another round of mass adoption without full transparency.
The Phase 1 trial includes 200 participants and focuses on safety and immune response over a short window. But like many familiar with the pitfalls of mRNA technology, Rose doubts whether past issues, like reactions to COVID shots and long-term risks, are being seriously considered.
We are thankful that experts like Dr. Rose are leading the call for public scrutiny and full transparency, warning that critical questions around safety, regulation, and licensing for these GMO products need real answers.
- Read more of Dr. Jessica Rose’s insights here: Substack on Self-Amplifying RNA
- Read the original news article here: BusinessWire Article
